APO Research
Talk to an analyst

APO RESEARCH · REPORT

Escitalopram

Compare research editions
View pricing & licenses

Selected research

Industry Research

Escitalopram Industry Research Report 2026

27 December 2025151 pages

Choose your research edition.

Industry ResearchEscitalopram Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Escitalopram Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Escitalopram Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Escitalopram Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Escitalopram Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Escitalopram market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Escitalopram is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Escitalopram is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Escitalopram is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Escitalopram include Accord Healthcare (IN), Amneal Pharmaceuticals (US), Apotex (CA), Aurobindo Pharma (IN), Forest Laboratories (US), Hetero Drugs (IN), Hikma Pharmaceuticals (UK), Hunan Dongting Pharmaceutical (CN) and Jewim Pharmaceutical (Shandong), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Escitalopram market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Escitalopram Market by Company

Accord Healthcare (IN)

Amneal Pharmaceuticals (US)

Apotex (CA)

Aurobindo Pharma (IN)

Forest Laboratories (US)

Hetero Drugs (IN)

Hikma Pharmaceuticals (UK)

Hunan Dongting Pharmaceutical (CN)

Jewim Pharmaceutical (Shandong)

Lundbeck (DK)

Lupin (IN)

Macleods Pharmaceuticals (IN)

Silarx Pharmacueticals (US)

TEVA (Israel)

Xidian Pharmaceutical (CN)

Zhejiang Conba Pharmaceutical (CN)

Mylan (US)

Novartis (US)

Sichuan Kelun Pharmaceutical (CN)

Xian Janssen Pharmaceutical (CN)

Zhejiang Huahai Pharmaceutical (CN)

Escitalopram Segment by Type

Tablets

Solution

Escitalopram Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Escitalopram Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Escitalopram market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Escitalopram and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Escitalopram.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Escitalopram manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Escitalopram by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Escitalopram in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Escitalopram Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Escitalopram Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Escitalopram Sales Market Share by Manufacturers (2021-2026) Table 8. Global Escitalopram Revenue of Manufacturers (2021-2026) Table 9. Global Escitalopram Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Escitalopram Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Escitalopram Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Escitalopram, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Escitalopram, Product Type & Application Table 14. Global Escitalopram Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Escitalopram by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Accord Healthcare (IN) Company Information Table 19. Accord Healthcare (IN) Business Overview Table 20. Accord Healthcare (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Accord Healthcare (IN) Escitalopram Product Portfolio Table 22. Accord Healthcare (IN) Recent Developments Table 23. Amneal Pharmaceuticals (US) Company Information Table 24. Amneal Pharmaceuticals (US) Business Overview Table 25. Amneal Pharmaceuticals (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Amneal Pharmaceuticals (US) Escitalopram Product Portfolio Table 27. Amneal Pharmaceuticals (US) Recent Developments Table 28. Apotex (CA) Company Information Table 29. Apotex (CA) Business Overview Table 30. Apotex (CA) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Apotex (CA) Escitalopram Product Portfolio Table 32. Apotex (CA) Recent Developments Table 33. Aurobindo Pharma (IN) Company Information Table 34. Aurobindo Pharma (IN) Business Overview Table 35. Aurobindo Pharma (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Aurobindo Pharma (IN) Escitalopram Product Portfolio Table 37. Aurobindo Pharma (IN) Recent Developments Table 38. Forest Laboratories (US) Company Information Table 39. Forest Laboratories (US) Business Overview Table 40. Forest Laboratories (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Forest Laboratories (US) Escitalopram Product Portfolio Table 42. Forest Laboratories (US) Recent Developments Table 43. Hetero Drugs (IN) Company Information Table 44. Hetero Drugs (IN) Business Overview Table 45. Hetero Drugs (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Hetero Drugs (IN) Escitalopram Product Portfolio Table 47. Hetero Drugs (IN) Recent Developments Table 48. Hikma Pharmaceuticals (UK) Company Information Table 49. Hikma Pharmaceuticals (UK) Business Overview Table 50. Hikma Pharmaceuticals (UK) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Hikma Pharmaceuticals (UK) Escitalopram Product Portfolio Table 52. Hikma Pharmaceuticals (UK) Recent Developments Table 53. Hunan Dongting Pharmaceutical (CN) Company Information Table 54. Hunan Dongting Pharmaceutical (CN) Business Overview Table 55. Hunan Dongting Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Hunan Dongting Pharmaceutical (CN) Escitalopram Product Portfolio Table 57. Hunan Dongting Pharmaceutical (CN) Recent Developments Table 58. Jewim Pharmaceutical (Shandong) Company Information Table 59. Jewim Pharmaceutical (Shandong) Business Overview Table 60. Jewim Pharmaceutical (Shandong) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Jewim Pharmaceutical (Shandong) Escitalopram Product Portfolio Table 62. Jewim Pharmaceutical (Shandong) Recent Developments Table 63. Lundbeck (DK) Company Information Table 64. Lundbeck (DK) Business Overview Table 65. Lundbeck (DK) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Lundbeck (DK) Escitalopram Product Portfolio Table 67. Lundbeck (DK) Recent Developments Table 68. Lupin (IN) Company Information Table 69. Lupin (IN) Business Overview Table 70. Lupin (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Lupin (IN) Escitalopram Product Portfolio Table 72. Lupin (IN) Recent Developments Table 73. Macleods Pharmaceuticals (IN) Company Information Table 74. Macleods Pharmaceuticals (IN) Business Overview Table 75. Macleods Pharmaceuticals (IN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Macleods Pharmaceuticals (IN) Escitalopram Product Portfolio Table 77. Macleods Pharmaceuticals (IN) Recent Developments Table 78. Silarx Pharmacueticals (US) Company Information Table 79. Silarx Pharmacueticals (US) Business Overview Table 80. Silarx Pharmacueticals (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Silarx Pharmacueticals (US) Escitalopram Product Portfolio Table 82. Silarx Pharmacueticals (US) Recent Developments Table 83. TEVA (Israel) Company Information Table 84. TEVA (Israel) Business Overview Table 85. TEVA (Israel) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. TEVA (Israel) Escitalopram Product Portfolio Table 87. TEVA (Israel) Recent Developments Table 88. Xidian Pharmaceutical (CN) Company Information Table 89. Xidian Pharmaceutical (CN) Business Overview Table 90. Xidian Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Xidian Pharmaceutical (CN) Escitalopram Product Portfolio Table 92. Xidian Pharmaceutical (CN) Recent Developments Table 93. Zhejiang Conba Pharmaceutical (CN) Company Information Table 94. Zhejiang Conba Pharmaceutical (CN) Business Overview Table 95. Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Zhejiang Conba Pharmaceutical (CN) Escitalopram Product Portfolio Table 97. Zhejiang Conba Pharmaceutical (CN) Recent Developments Table 98. Mylan (US) Company Information Table 99. Mylan (US) Business Overview Table 100. Mylan (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Mylan (US) Escitalopram Product Portfolio Table 102. Mylan (US) Recent Developments Table 103. Novartis (US) Company Information Table 104. Novartis (US) Business Overview Table 105. Novartis (US) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Novartis (US) Escitalopram Product Portfolio Table 107. Novartis (US) Recent Developments Table 108. Sichuan Kelun Pharmaceutical (CN) Company Information Table 109. Sichuan Kelun Pharmaceutical (CN) Business Overview Table 110. Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sichuan Kelun Pharmaceutical (CN) Escitalopram Product Portfolio Table 112. Sichuan Kelun Pharmaceutical (CN) Recent Developments Table 113. Xian Janssen Pharmaceutical (CN) Company Information Table 114. Xian Janssen Pharmaceutical (CN) Business Overview Table 115. Xian Janssen Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Xian Janssen Pharmaceutical (CN) Escitalopram Product Portfolio Table 117. Xian Janssen Pharmaceutical (CN) Recent Developments Table 118. Zhejiang Huahai Pharmaceutical (CN) Company Information Table 119. Zhejiang Huahai Pharmaceutical (CN) Business Overview Table 120. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product Portfolio Table 122. Zhejiang Huahai Pharmaceutical (CN) Recent Developments Table 123. Global Escitalopram Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 124. Global Escitalopram Sales by Region (2021-2026) & (K Units) Table 125. Global Escitalopram Sales Market Share by Region (2021-2026) Table 126. Global Escitalopram Sales by Region (2027-2032) & (K Units) Table 127. Global Escitalopram Sales Market Share by Region (2027-2032) Table 128. Global Escitalopram Revenue by Region (2021-2026) & (US$ Million) Table 129. Global Escitalopram Revenue Market Share by Region (2021-2026) Table 130. Global Escitalopram Revenue by Region (2027-2032) & (US$ Million) Table 131. Global Escitalopram Revenue Market Share by Region (2027-2032) Table 132. North America Escitalopram Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. North America Escitalopram Sales by Country (2021-2026) & (K Units) Table 134. North America Escitalopram Sales by Country (2027-2032) & (K Units) Table 135. North America Escitalopram Revenue by Country (2021-2026) & (US$ Million) Table 136. North America Escitalopram Revenue by Country (2027-2032) & (US$ Million) Table 137. Europe Escitalopram Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Europe Escitalopram Sales by Country (2021-2026) & (K Units) Table 139. Europe Escitalopram Sales by Country (2027-2032) & (K Units) Table 140. Europe Escitalopram Revenue by Country (2021-2026) & (US$ Million) Table 141. Europe Escitalopram Revenue by Country (2027-2032) & (US$ Million) Table 142. Asia Pacific Escitalopram Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Asia Pacific Escitalopram Sales by Country (2021-2026) & (K Units) Table 144. Asia Pacific Escitalopram Sales by Country (2027-2032) & (K Units) Table 145. Asia Pacific Escitalopram Revenue by Country (2021-2026) & (US$ Million) Table 146. Asia Pacific Escitalopram Revenue by Country (2027-2032) & (US$ Million) Table 147. South America Escitalopram Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. South America Escitalopram Sales by Country (2021-2026) & (K Units) Table 149. South America Escitalopram Sales by Country (2027-2032) & (K Units) Table 150. South America Escitalopram Revenue by Country (2021-2026) & (US$ Million) Table 151. South America Escitalopram Revenue by Country (2027-2032) & (US$ Million) Table 152. Middle East and Africa Escitalopram Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Middle East and Africa Escitalopram Sales by Country (2021-2026) & (K Units) Table 154. Middle East and Africa Escitalopram Sales by Country (2027-2032) & (K Units) Table 155. Middle East and Africa Escitalopram Revenue by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Escitalopram Revenue by Country (2027-2032) & (US$ Million) Table 157. Global Escitalopram Sales by Type (2021-2026) & (K Units) Table 158. Global Escitalopram Sales by Type (2027-2032) & (K Units) Table 159. Global Escitalopram Sales Market Share by Type (2021-2026) Table 160. Global Escitalopram Sales Market Share by Type (2027-2032) Table 161. Global Escitalopram Revenue by Type (2021-2026) & (US$ Million) Table 162. Global Escitalopram Revenue by Type (2027-2032) & (US$ Million) Table 163. Global Escitalopram Revenue Market Share by Type (2021-2026) Table 164. Global Escitalopram Revenue Market Share by Type (2027-2032) Table 165. Global Escitalopram Price by Type (2021-2026) & (US$/Unit) Table 166. Global Escitalopram Price by Type (2027-2032) & (US$/Unit) Table 167. Global Escitalopram Sales by Application (2021-2026) & (K Units) Table 168. Global Escitalopram Sales by Application (2027-2032) & (K Units) Table 169. Global Escitalopram Sales Market Share by Application (2021-2026) Table 170. Global Escitalopram Sales Market Share by Application (2027-2032) Table 171. Global Escitalopram Revenue by Application (2021-2026) & (US$ Million) Table 172. Global Escitalopram Revenue by Application (2027-2032) & (US$ Million) Table 173. Global Escitalopram Revenue Market Share by Application (2021-2026) Table 174. Global Escitalopram Revenue Market Share by Application (2027-2032) Table 175. Global Escitalopram Price by Application (2021-2026) & (US$/Unit) Table 176. Global Escitalopram Price by Application (2027-2032) & (US$/Unit) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Escitalopram Distributors List Table 180. Escitalopram Customers List Table 181. Escitalopram Industry Trends Table 182. Escitalopram Industry Drivers Table 183. Escitalopram Industry Restraints Table 184. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Escitalopram Product Image Figure 5. Global Escitalopram Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Escitalopram Market Size (2021-2032) & (US$ Million) Figure 7. Global Escitalopram Sales (2021-2032) & (K Units) Figure 8. Global Escitalopram Average Price (US$/Unit) & (2021-2032) Figure 9. Tablets Product Image Figure 10. Solution Product Image Figure 11. Retail Pharmacies Product Image Figure 12. Online Pharmacies Product Image Figure 13. Hospital Pharmacies Product Image Figure 14. Global Escitalopram Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Escitalopram, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Escitalopram Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Escitalopram Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Escitalopram Sales by Region in 2025 Figure 20. Global Escitalopram Revenue by Region in 2025 Figure 21. North America Escitalopram Market Size by Country in 2025 Figure 22. North America Escitalopram Sales Market Share by Country (2021-2032) Figure 23. North America Escitalopram Revenue Market Share by Country (2021-2032) Figure 24. United States Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Escitalopram Market Size by Country in 2025 Figure 28. Europe Escitalopram Sales Market Share by Country (2021-2032) Figure 29. Europe Escitalopram Revenue Market Share by Country (2021-2032) Figure 30. Germany Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Escitalopram Market Size by Country in 2025 Figure 41. Asia Pacific Escitalopram Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Escitalopram Revenue Market Share by Country (2021-2032) Figure 43. China Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Escitalopram Market Size by Country in 2025 Figure 52. South America Escitalopram Sales Market Share by Country (2021-2032) Figure 53. South America Escitalopram Revenue Market Share by Country (2021-2032) Figure 54. Brazil Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Colombia Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Escitalopram Market Size by Country in 2025 Figure 59. Middle East and Africa Escitalopram Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Escitalopram Revenue Market Share by Country (2021-2032) Figure 61. Egypt Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Escitalopram Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Escitalopram Sales Market Share by Type (2021-2032) Figure 67. Global Escitalopram Revenue Market Share by Type (2021-2032) Figure 68. Global Escitalopram Price (US$/Unit) by Type (2021-2032) Figure 69. Global Escitalopram Sales Market Share by Application (2021-2032) Figure 70. Global Escitalopram Revenue Market Share by Application (2021-2032) Figure 71. Global Escitalopram Price (US$/Unit) by Application (2021-2032) Figure 72. Escitalopram Value Chain Figure 73. Escitalopram Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Escitalopram Industry Opportunities and Challenges

Scope & coverage.

Types
  • Tablets
  • Solution
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Accord Healthcare (IN)
  • Amneal Pharmaceuticals (US)
  • Apotex (CA)
  • Aurobindo Pharma (IN)
  • Forest Laboratories (US)
  • Hetero Drugs (IN)
  • Hikma Pharmaceuticals (UK)
  • Hunan Dongting Pharmaceutical (CN)
  • Jewim Pharmaceutical (Shandong)
  • Lundbeck (DK)
  • Lupin (IN)
  • Macleods Pharmaceuticals (IN)
  • Silarx Pharmacueticals (US)
  • TEVA (Israel)
  • Xidian Pharmaceutical (CN)
  • Zhejiang Conba Pharmaceutical (CN)
  • Mylan (US)
  • Novartis (US)
  • Sichuan Kelun Pharmaceutical (CN)
  • Xian Janssen Pharmaceutical (CN)
  • Zhejiang Huahai Pharmaceutical (CN)

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Escitalopram Market Size (2021-2032)
  4. 2.2.2 Global Escitalopram Sales (2021-2032)
  5. 2.2.3 Global Escitalopram Market Average Price (2021-2032)
  6. 2.3 Escitalopram by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Tablets
  9. 2.3.3 Solution
  10. 2.4 Escitalopram by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Retail Pharmacies
  13. 2.4.3 Online Pharmacies
  14. 2.4.4 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Escitalopram Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Escitalopram Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Escitalopram Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Escitalopram Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Escitalopram Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Escitalopram, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Escitalopram, Product Type & Application
  8. 3.8 Global Manufacturers of Escitalopram, Established Date
  9. 3.9 Global Escitalopram Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Accord Healthcare (IN)
  2. 4.1.1 Accord Healthcare (IN) Company Information
  3. 4.1.2 Accord Healthcare (IN) Business Overview
  4. 4.1.3 Accord Healthcare (IN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Accord Healthcare (IN) Escitalopram Product Portfolio
  6. 4.1.5 Accord Healthcare (IN) Recent Developments
  7. 4.2 Amneal Pharmaceuticals (US)
  8. 4.2.1 Amneal Pharmaceuticals (US) Company Information
  9. 4.2.2 Amneal Pharmaceuticals (US) Business Overview
  10. 4.2.3 Amneal Pharmaceuticals (US) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Amneal Pharmaceuticals (US) Escitalopram Product Portfolio
  12. 4.2.5 Amneal Pharmaceuticals (US) Recent Developments
  13. 4.3 Apotex (CA)
  14. 4.3.1 Apotex (CA) Company Information
  15. 4.3.2 Apotex (CA) Business Overview
  16. 4.3.3 Apotex (CA) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Apotex (CA) Escitalopram Product Portfolio
  18. 4.3.5 Apotex (CA) Recent Developments
  19. 4.4 Aurobindo Pharma (IN)
  20. 4.4.1 Aurobindo Pharma (IN) Company Information
  21. 4.4.2 Aurobindo Pharma (IN) Business Overview
  22. 4.4.3 Aurobindo Pharma (IN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Aurobindo Pharma (IN) Escitalopram Product Portfolio
  24. 4.4.5 Aurobindo Pharma (IN) Recent Developments
  25. 4.5 Forest Laboratories (US)
  26. 4.5.1 Forest Laboratories (US) Company Information
  27. 4.5.2 Forest Laboratories (US) Business Overview
  28. 4.5.3 Forest Laboratories (US) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Forest Laboratories (US) Escitalopram Product Portfolio
  30. 4.5.5 Forest Laboratories (US) Recent Developments
  31. 4.6 Hetero Drugs (IN)
  32. 4.6.1 Hetero Drugs (IN) Company Information
  33. 4.6.2 Hetero Drugs (IN) Business Overview
  34. 4.6.3 Hetero Drugs (IN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Hetero Drugs (IN) Escitalopram Product Portfolio
  36. 4.6.5 Hetero Drugs (IN) Recent Developments
  37. 4.7 Hikma Pharmaceuticals (UK)
  38. 4.7.1 Hikma Pharmaceuticals (UK) Company Information
  39. 4.7.2 Hikma Pharmaceuticals (UK) Business Overview
  40. 4.7.3 Hikma Pharmaceuticals (UK) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Hikma Pharmaceuticals (UK) Escitalopram Product Portfolio
  42. 4.7.5 Hikma Pharmaceuticals (UK) Recent Developments
  43. 4.8 Hunan Dongting Pharmaceutical (CN)
  44. 4.8.1 Hunan Dongting Pharmaceutical (CN) Company Information
  45. 4.8.2 Hunan Dongting Pharmaceutical (CN) Business Overview
  46. 4.8.3 Hunan Dongting Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hunan Dongting Pharmaceutical (CN) Escitalopram Product Portfolio
  48. 4.8.5 Hunan Dongting Pharmaceutical (CN) Recent Developments
  49. 4.9 Jewim Pharmaceutical (Shandong)
  50. 4.9.1 Jewim Pharmaceutical (Shandong) Company Information
  51. 4.9.2 Jewim Pharmaceutical (Shandong) Business Overview
  52. 4.9.3 Jewim Pharmaceutical (Shandong) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jewim Pharmaceutical (Shandong) Escitalopram Product Portfolio
  54. 4.9.5 Jewim Pharmaceutical (Shandong) Recent Developments
  55. 4.10 Lundbeck (DK)
  56. 4.10.1 Lundbeck (DK) Company Information
  57. 4.10.2 Lundbeck (DK) Business Overview
  58. 4.10.3 Lundbeck (DK) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lundbeck (DK) Escitalopram Product Portfolio
  60. 4.10.5 Lundbeck (DK) Recent Developments
  61. 4.11 Lupin (IN)
  62. 4.11.1 Lupin (IN) Company Information
  63. 4.11.2 Lupin (IN) Business Overview
  64. 4.11.3 Lupin (IN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Lupin (IN) Escitalopram Product Portfolio
  66. 4.11.5 Lupin (IN) Recent Developments
  67. 4.12 Macleods Pharmaceuticals (IN)
  68. 4.12.1 Macleods Pharmaceuticals (IN) Company Information
  69. 4.12.2 Macleods Pharmaceuticals (IN) Business Overview
  70. 4.12.3 Macleods Pharmaceuticals (IN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Macleods Pharmaceuticals (IN) Escitalopram Product Portfolio
  72. 4.12.5 Macleods Pharmaceuticals (IN) Recent Developments
  73. 4.13 Silarx Pharmacueticals (US)
  74. 4.13.1 Silarx Pharmacueticals (US) Company Information
  75. 4.13.2 Silarx Pharmacueticals (US) Business Overview
  76. 4.13.3 Silarx Pharmacueticals (US) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Silarx Pharmacueticals (US) Escitalopram Product Portfolio
  78. 4.13.5 Silarx Pharmacueticals (US) Recent Developments
  79. 4.14 TEVA (Israel)
  80. 4.14.1 TEVA (Israel) Company Information
  81. 4.14.2 TEVA (Israel) Business Overview
  82. 4.14.3 TEVA (Israel) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 TEVA (Israel) Escitalopram Product Portfolio
  84. 4.14.5 TEVA (Israel) Recent Developments
  85. 4.15 Xidian Pharmaceutical (CN)
  86. 4.15.1 Xidian Pharmaceutical (CN) Company Information
  87. 4.15.2 Xidian Pharmaceutical (CN) Business Overview
  88. 4.15.3 Xidian Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Xidian Pharmaceutical (CN) Escitalopram Product Portfolio
  90. 4.15.5 Xidian Pharmaceutical (CN) Recent Developments
  91. 4.16 Zhejiang Conba Pharmaceutical (CN)
  92. 4.16.1 Zhejiang Conba Pharmaceutical (CN) Company Information
  93. 4.16.2 Zhejiang Conba Pharmaceutical (CN) Business Overview
  94. 4.16.3 Zhejiang Conba Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Zhejiang Conba Pharmaceutical (CN) Escitalopram Product Portfolio
  96. 4.16.5 Zhejiang Conba Pharmaceutical (CN) Recent Developments
  97. 4.17 Mylan (US)
  98. 4.17.1 Mylan (US) Company Information
  99. 4.17.2 Mylan (US) Business Overview
  100. 4.17.3 Mylan (US) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Mylan (US) Escitalopram Product Portfolio
  102. 4.17.5 Mylan (US) Recent Developments
  103. 4.18 Novartis (US)
  104. 4.18.1 Novartis (US) Company Information
  105. 4.18.2 Novartis (US) Business Overview
  106. 4.18.3 Novartis (US) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Novartis (US) Escitalopram Product Portfolio
  108. 4.18.5 Novartis (US) Recent Developments
  109. 4.19 Sichuan Kelun Pharmaceutical (CN)
  110. 4.19.1 Sichuan Kelun Pharmaceutical (CN) Company Information
  111. 4.19.2 Sichuan Kelun Pharmaceutical (CN) Business Overview
  112. 4.19.3 Sichuan Kelun Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Sichuan Kelun Pharmaceutical (CN) Escitalopram Product Portfolio
  114. 4.19.5 Sichuan Kelun Pharmaceutical (CN) Recent Developments
  115. 4.20 Xian Janssen Pharmaceutical (CN)
  116. 4.20.1 Xian Janssen Pharmaceutical (CN) Company Information
  117. 4.20.2 Xian Janssen Pharmaceutical (CN) Business Overview
  118. 4.20.3 Xian Janssen Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Xian Janssen Pharmaceutical (CN) Escitalopram Product Portfolio
  120. 4.20.5 Xian Janssen Pharmaceutical (CN) Recent Developments
  121. 4.21 Zhejiang Huahai Pharmaceutical (CN)
  122. 4.21.1 Zhejiang Huahai Pharmaceutical (CN) Company Information
  123. 4.21.2 Zhejiang Huahai Pharmaceutical (CN) Business Overview
  124. 4.21.3 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Zhejiang Huahai Pharmaceutical (CN) Escitalopram Product Portfolio
  126. 4.21.5 Zhejiang Huahai Pharmaceutical (CN) Recent Developments
5 Global Escitalopram Market Scenario by Region
  1. 5.1 Global Escitalopram Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Escitalopram Sales by Region: 2021-2032
  3. 5.2.1 Global Escitalopram Sales by Region: 2021-2026
  4. 5.2.2 Global Escitalopram Sales by Region: 2027-2032
  5. 5.3 Global Escitalopram Revenue by Region: 2021-2032
  6. 5.3.1 Global Escitalopram Revenue by Region: 2021-2026
  7. 5.3.2 Global Escitalopram Revenue by Region: 2027-2032
  8. 5.4 North America Escitalopram Market Facts & Figures by Country
  9. 5.4.1 North America Escitalopram Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Escitalopram Sales by Country (2021-2032)
  11. 5.4.3 North America Escitalopram Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Escitalopram Market Facts & Figures by Country
  16. 5.5.1 Europe Escitalopram Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Escitalopram Sales by Country (2021-2032)
  18. 5.5.3 Europe Escitalopram Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Escitalopram Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Escitalopram Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Escitalopram Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Escitalopram Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Escitalopram Market Facts & Figures by Country
  41. 5.7.1 South America Escitalopram Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Escitalopram Sales by Country (2021-2032)
  43. 5.7.3 South America Escitalopram Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Escitalopram Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Escitalopram Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Escitalopram Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Escitalopram Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Escitalopram Sales by Type (2021-2032)
  2. 6.1.1 Global Escitalopram Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Escitalopram Sales Market Share by Type (2021-2032)
  4. 6.2 Global Escitalopram Revenue by Type (2021-2032)
  5. 6.2.1 Global Escitalopram Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Escitalopram Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Escitalopram Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Escitalopram Sales by Application (2021-2032)
  2. 7.1.1 Global Escitalopram Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Escitalopram Sales Market Share by Application (2021-2032)
  4. 7.2 Global Escitalopram Revenue by Application (2021-2032)
  5. 7.2.1 Global Escitalopram Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Escitalopram Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Escitalopram Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Escitalopram Value Chain Analysis
  2. 8.1.1 Escitalopram Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Escitalopram Production Mode & Process
  5. 8.2 Escitalopram Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Escitalopram Distributors
  8. 8.2.3 Escitalopram Customers
9 Global Escitalopram Analyzing Market Dynamics
  1. 9.1 Escitalopram Industry Trends
  2. 9.2 Escitalopram Industry Drivers
  3. 9.3 Escitalopram Industry Opportunities and Challenges
  4. 9.4 Escitalopram Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst